{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:44:08Z","timestamp":1768484648821,"version":"3.49.0"},"posted":{"date-parts":[[2018,11,30]]},"group-title":"Cancer Biology","reference-count":28,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Late diagnosis, modest treatment options and lack of predictive markers of therapy response dictate the poor overall survival (OS) of \u223c1 year in most gastric cancer (GC) patients. We hypothesized that the level of CD44v6 expression in tumor cells could predict therapy response and prognosis in GC patients.<\/jats:p>\n                <jats:p>We analyzed a surgical tumor series of GC patients for the extension of CD44v6 membranous immuno-expression, clinical-pathological features, patient survival, and response to therapy. By integrating this information, we assessed the value of CD44v6 expression to predict benefit from current treatment regimens and prognosis in GC patients. We used GC cell lines and mouse xenografts to assess and\/validate the biological impact of CD44v6 expression in GC cells behavior.<\/jats:p>\n                <jats:p>\n                  We demonstrated that GC patients whose tumors present higher levels of CD44v6 membranous expression benefit from adding chemotherapy to surgery as opposed to those without CD44v6 expression. Moreover, patients bearing CD44_high tumors presented worse OS than those bearing CD44_absent\/low tumors, consolidating the role of CD44v6 expression as an independent factor of poor prognosis in this disease. Finally, our\n                  <jats:italic>in vitro<\/jats:italic>\n                  and patients\u2019 data pinpoints the CD44v6+ cell population as the driver of tumor recurrence following conventional chemotherapy, in heterogeneous tumors composed by CD44v6- and CD44v6+ cells.\n                <\/jats:p>\n                <jats:p>Our study pioneers the identification of CD44v6 as a potential predictive marker of response to conventional chemotherapy, and consolidates CD44v6 as an independent marker of poor prognosis in GC. Overall, our data strongly supports selection of patients with high CD44v6 expressing tumors for conventional chemotherapy with or without surgery, regardless of the TNM stage.<\/jats:p>","DOI":"10.1101\/468934","type":"posted-content","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T15:25:21Z","timestamp":1543591521000},"source":"Crossref","is-referenced-by-count":2,"title":["CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-0764","authenticated-orcid":false,"given":"Carla","family":"Pereira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-1460","authenticated-orcid":false,"given":"Daniel","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9803-9584","authenticated-orcid":false,"given":"Carolina","family":"Lemos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-8992","authenticated-orcid":false,"given":"Diana","family":"Martins","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-2277","authenticated-orcid":false,"given":"Nuno","family":"Mendes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-7394","authenticated-orcid":false,"given":"Daniela","family":"Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2761-4929","authenticated-orcid":false,"given":"Pedro","family":"Granja","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-1006","authenticated-orcid":false,"given":"F\u00e1tima","family":"Carneiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-1633","authenticated-orcid":false,"given":"Raquel","family":"Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-7394","authenticated-orcid":false,"given":"Gabriela M","family":"Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-2264","authenticated-orcid":false,"given":"Carla","family":"Oliveira","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2019072211430048000_468934v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2019072211430048000_468934v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.016"},{"key":"2019072211430048000_468934v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.09.007"},{"key":"2019072211430048000_468934v1.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-013-1533-y"},{"key":"2019072211430048000_468934v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2019072211430048000_468934v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5"},{"key":"2019072211430048000_468934v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(97)00152-0"},{"key":"2019072211430048000_468934v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1004"},{"key":"2019072211430048000_468934v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.07.011"},{"key":"2019072211430048000_468934v1.10","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950170106"},{"key":"2019072211430048000_468934v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2008.03.015"},{"key":"2019072211430048000_468934v1.12","first-page":"18","article-title":"CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells","volume":"5","year":"2017","journal-title":"Front Cell Dev Biol"},{"key":"2019072211430048000_468934v1.13","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2015-0048"},{"key":"2019072211430048000_468934v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.01.009"},{"key":"2019072211430048000_468934v1.15","first-page":"235","article-title":"CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells","volume":"6","year":"2015","journal-title":"Front Immunol"},{"key":"2019072211430048000_468934v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2010.155"},{"key":"2019072211430048000_468934v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2014.08.001"},{"key":"2019072211430048000_468934v1.18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00432-015-1964-8","article-title":"Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer","volume":"141","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019072211430048000_468934v1.19","doi-asserted-by":"crossref","first-page":"45848","DOI":"10.18632\/oncotarget.17435","article-title":"Regulation of CD44v6 expression in gastric carcinoma by the IL-6\/STAT3 signaling pathway and its clinical significance","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2019072211430048000_468934v1.20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10561-008-9102-3","article-title":"Establishment of a Tumour Bank: the experience of the Department of Pathology of Hospital S. Jo\u00e3o (Porto, Portugal","volume":"10","year":"2009","journal-title":"Cell Tissue Bank"},{"key":"2019072211430048000_468934v1.21","first-page":"91","article-title":"Establishment and characterization of two cell lines derived from human diffuse gastric carcinomas xenografted in nude mice","volume":"428","year":"1996","journal-title":"Virchows Arch"},{"key":"2019072211430048000_468934v1.22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/ejhg.2013.292","article-title":"Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA","volume":"22","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"2019072211430048000_468934v1.23","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1007\/s13277-015-4755-6","article-title":"Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells","volume":"37","year":"2016","journal-title":"Tumour Biol"},{"key":"2019072211430048000_468934v1.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2016.05.012","article-title":"The role of CD44 in glioblastoma multiforme","volume":"34","year":"2016","journal-title":"J Clin Neurosci"},{"key":"2019072211430048000_468934v1.25","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.18632\/oncotarget.14163","article-title":"CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2019072211430048000_468934v1.26","first-page":"41","article-title":"CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer","volume":"11","year":"2004","journal-title":"Oncol Rep"},{"key":"2019072211430048000_468934v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.10.009"},{"key":"2019072211430048000_468934v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.03.002"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/468934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:17:50Z","timestamp":1768432670000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/468934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1101\/468934","relation":{},"subject":[],"published":{"date-parts":[[2018,11,30]]},"subtype":"preprint"}}